KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Financing Activities: 2013-2025

Historic Cash from Financing Activities for Xenon Pharmaceuticals (XENE) over the last 9 years, with Sep 2025 value amounting to $2.4 million.

  • Xenon Pharmaceuticals' Cash from Financing Activities was N/A to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year change of. This contributed to the annual value of $12.1 million for FY2024, which is 96.57% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Cash from Financing Activities stood at $2.4 million, which was up 3,530.77% from $65,000 recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Cash from Financing Activities high stood at $324.0 million for Q4 2023, and its period low was $6,000 during Q4 2022.
  • In the last 3 years, Xenon Pharmaceuticals' Cash from Financing Activities had a median value of $2.4 million in 2025 and averaged $67.9 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Cash from Financing Activities plummeted by 100.00% in 2022, and later surged by 5,400,133.33% in 2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $324.0 million in 2021, then crashed by 100.00% to $6,000 in 2022, then spiked by 5,400,133.33% to $324.0 million in 2023, then slumped by 96.26% to $12.1 million in 2024, then reached $2.4 million in 2025.
  • Its Cash from Financing Activities stands at $2.4 million for Q3 2025, versus $65,000 for Q2 2025 and $1.2 million for Q1 2025.